Felip, E., Gray, J. E., Ward, J., Casarini, I., Maturana, R. U., O'Byrne, K. J., Lee, D. H., Yang, J. C. H., Bigot, F., Ferrara, R., Kowalski, D., Nadal, E., Banerjee, J. K., Keidel, S., Chen, H., Bhagwati, N. S., Eiras, R., Erman, M. (2026). INTerpath-013: A phase 2, randomized, double-blind study of intismeran autogene plus pembrolizumab and chemotherapy as first-line treatment for metastatic squamous non–small cell lung cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8670